The Community Guide

- gsearch

Search Results

Narrow Results:

2021 2
2017 2
2014 1

Journal Article 5

1 - 5 of 5 Results

Refine Results

Refine Results:

Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort

CITE Title : Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort Personal Author(s) : Bruden, Dana JT;McMahon, Brian J.;Townshend-Bulson, Lisa;Gounder, Prabhu;Gove, Jim;Plotnik, Julia;Homan, Chriss;Hewitt, Annette;Barbour, Youssef;Spradling, Philip R.;Simons, Brenna C.;McArdle, Susan;Bruce, Michael; Published Date : 7 2017;7-2017; Source : Hepatology. 66(1):37-45 URL : https://stacks.cdc.gov/view/cdc/46648 Bruden, Dana JT et al. (2017). Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort. 66(1). Bruden, Dana JT et al. "Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort" 66, no. 1 (2017) Bruden, Dana JT et al. "Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort" vol. 66, no. 1, 2017 Export RIS Citation Information.

:

Bruden, Dana JT ;

McMahon, Brian J.

7 2017 | Hepatology. 66(1):37-45

:

ConclusionFor prevention of HCC, LRD and ESLD in the short-term, HCV therapy should target those with more than mild fibrosis.
Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska

CITE Title : Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska Personal Author(s) : Ramaswamy, Maya;Bruden, Dana;Nolen, Leisha D.;Mosites, Emily;Snowball, Mary;Nelson, Noele P.;Bruce, Michael;McMahon, Brian J.; Published Date : 6 2021;6-2021; Source : J Med Virol. 93(6):3991-3994 URL : https://stacks.cdc.gov/view/cdc/148996 Ramaswamy, Maya et al. (2021). Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska. 93(6). Ramaswamy, Maya et al. "Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska" 93, no. 6 (2021) Ramaswamy, Maya et al. "Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska" vol. 93, no. 6, 2021 Export RIS Citation Information.

:

Ramaswamy, Maya ;

Bruden, Dana

6 2021 | J Med Virol. 93(6):3991-3994

:

The hepatitis A vaccine is recommended for all children greater than or equal to 1 year of age, however, the duration of vaccine protection is unknown...
Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death

CITE Title : Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death Personal Author(s) : McMahon, Brian J;Bruden, Dana;Townshend-Bulson, Lisa;Simons, Brenna;Spradling, Phillip;Livingston, Stephen;Gove, James;Hewitt, Annette;Plotnik, Julia;Homan, Chriss;Espera, Hannah;Negus, Susan;Snowball, Mary;Barbour, Youssef;Bruce, Michael;Gounder, Prabhu; Published Date : 3 2017;3-2017; Source : Clin Gastroenterol Hepatol. 15(3):431-437.e2 URL : https://stacks.cdc.gov/view/cdc/44267 McMahon, Brian J et al. (2017). Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death. 15(3). McMahon, Brian J et al. "Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death" 15, no. 3 (2017) McMahon, Brian J et al. "Infection With Hepatitis C Virus Genotype 3 is an Independent Risk Factor for End-stage Liver Disease, Hepatocellular Carcinoma, and Liver-related Death" vol. 15, no. 3, 2017 Export RIS Citation Information.

:

McMahon, Brian J ;

Bruden, Dana

3 2017 | Clin Gastroenterol Hepatol. 15(3):431-437.e2

:

Background & AimsFew studies have examined factors associated with disease progression in hepatitis C virus (HCV) infection. We examined the associati...
HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study

CITE Title : HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study Personal Author(s) : McMahon, Brian J.;Nolen, Leisha D.;Snowball, Mary;Homan, Chriss;Negus, Susan;Roik, Elena;Spradling, Philip R.;Bruden, Dana; Published Date : 12 2021;12-2021; Source : Hepatology. 74(6):2965-2973 URL : https://stacks.cdc.gov/view/cdc/151682 McMahon, Brian J. et al. (2021). HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study. 74(6). McMahon, Brian J. et al. "HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study" 74, no. 6 (2021) McMahon, Brian J. et al. "HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study" vol. 74, no. 6, 2021 Export RIS Citation Information.

:

McMahon, Brian J. ;

Nolen, Leisha D.

12 2021 | Hepatology. 74(6):2965-2973

:

BACKGROUND AND AIMS:Information is limited regarding HBV genotype and the outcome of chronic HBV (CHB) infection. We examined the effect of HBV genoty...
Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease

CITE Title : Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease Personal Author(s) : McMahon, Brian J;Bulkow, Lisa;Simons, Brenna;Zhang, Yuhong;Negus, Susan;Homan, Chriss;Spradling, Philip;Teshale, Eyasu;Lau, Daryl;Snowball, Mary;Livingston, Stephen; Published Date : 4 2014;4-2014; Source : Clin Gastroenterol Hepatol. 12(4):701-6.e1-3 URL : https://stacks.cdc.gov/view/cdc/35090 McMahon, Brian J et al. (2014). Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease. 12(4). McMahon, Brian J et al. "Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease" 12, no. 4 (2014) McMahon, Brian J et al. "Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease" vol. 12, no. 4, 2014 Export RIS Citation Information.

:

McMahon, Brian J ;

Bulkow, Lisa

4 2014 | Clin Gastroenterol Hepatol. 12(4):701-6.e1-3

:

ConclusionOf participants, 26% met criteria for immune active HBV. An HBV DNA level of > 20,000 IU/ml was strongly correlated with persons meeting the...